J&J antes $50M to get Zymework­s' 6th big bis­pecifics al­liance un­der­way, with $6B in to­tal mile­stones on the ta­ble

New­ly pub­lic Zymeworks $ZYME has just lined up its 6th ma­jor bio­phar­ma dis­cov­ery al­liance, this time bring­ing J&J $JNJ in­to a fold that al­ready in­cludes such big play­ers as Mer­ck, Eli Lil­ly, Cel­gene, GSK and Dai­ichi Sankyo. And this deal starts with a sub­stan­tial — for a dis­cov­ery deal — up­front along with $1.4 bil­lion in to­tal mile­stones on the ta­ble.

Zymeworks’ some­what bat­tered shares took off on the news, spik­ing 38% Mon­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER